JGH: Discontinuation of 5-aminosalicylic acid in patients with ulcerative colitis in remission does not increase risk of disease recurrence

As early as the 1940s scientists observed that salicylic acid-sulfasalazine (SASP) in the treatment of rheumatoid arthritis, the associated colitis also improved
.

It was not until 1977 that Hanauer et al.

Ulcerative colitis 5-aminosalicylic acid is the drug of choice for the treatment of ulcerative colitis

 

This is a retrospective cohort study using the Hong Kong territory-wide healthcare database
.

The primary outcome was the occurrence of a UC flare, which was defined as the use of new corticosteroids or UC-related hospitalization in UC patients within 5 years

statistical immunity

A total of 1,408 patients were finally included in this study, with a median follow-up of 41.

8 months [interquartile range (IQR): 17.

Taken together, the researchers concluded that cessation of 5-ASA in UC patients with glucocorticoid-free remission ≥1 year was not associated with an increased risk of relapse, therefore, future prospective trials should evaluate the effect of cessation of 5-ASA in patients with stable UC.
role
.

Taken together, the researchers concluded that cessation of 5-ASA in UC patients with glucocorticoid-free remission ≥1 year was not associated with an increased risk of relapse, therefore, future prospective trials should evaluate the effect of cessation of 5-ASA in patients with stable UC.
role
.

Original source:

Original source:

Joyce WY Mak.

Joyce WY Mak.
Et al.
Stopping 5-Aminosalicylic Acid in Ulcerative Colitis Patients in Corticosteroid-free remission is not associated with Increased Risk of Flare: A Territory-wide population-based cohort study.
.
2022.
JGH.
Stopping 5-Aminosalicylic Acid in Ulcerative Colitis Patients in Corticosteroid-free remission is not associated with Increased Risk of Flare: A Territory-wide population-based cohort study.
Leave a comment here